

### My InSPIREd Life

#### In Vitro Drug Sensitivity Assay on CLL cells


Fudan University Yun Li

09/09/2022

Walter and Eliza Hall Institute of Medical Research



# Project Background: Chronic lymphocytic leukaemia



Immunophenotype in CLL and other lymphoproliferative disorders.

Markers	CLL	MCL	SMZL	B-PLL
CD19	+	+	+	+
CD5	+	+	+/_	+/_
CD20	dim	+	+	+
CD23	+	_	+/_	_
FMC7	-	+	+/_	+
Light chain	dim	Bright	Bright	Bright
Heavy chain	IgM/IgD	IgM/IgD	IgM/IgD	IgM/IgD
CD200	+	_	+/_	+/-

CLL: chronic lymphocytic leukaemia; MCL: mantle cell lymphoma; SMZL: splenic marginal zone lymphoma; B-PLL: B-cell prolymphocytic leukaemia.

Chronic lymphocytic leukaemia (CLL) is a type of slow-growing leukaemia that affects developing B-lymphocytes with a high incidence.

#### **CLL cell surface marker:**


$$CD5 + CD19 +$$

doi: 10.1038/s41571-019-0239-8.

doi: 10.1016/j.critrevonc.2016.06.003.

## Project Background: Treatments

#### BH3-mimetic Drugs: Venetoclax



Venetoclax is a Bcl-2 inhibitor, playing its role by attaching to Bcl-2 to block its function. This activates BAX and BAK, making cells begin to apoptosis.


#### **Hypothesis:**

CLL cells can be killed by Venetoclax, and Emrisacan can strengthen the effect by activating necroptosis.

doi: 10.1016/j.ccell.2018.11.004.

doi: 10.1016/bs.apcsb.2021.01.003.


#### Venetoclax Kill Curve



	CD19+CD5+ CLL Cells	RS4;11
HillSlope	-0.2300	-0.5980
IC50	0.01691	4.416


CLL cells are sensitive to killing by Venetoclax

### **Drug Assay on CLL Cells**



Live Cell Concentrations (cells/uL)						
TNF (10ng/mL) - + + + + +						+
EMR(uM)	0	0	1	5	25	25
Venetoclax (2.5uM)	-	-	-	-	-	+
CD19+ CD5+	92.29	210.92	211.49	229.09	426.04	64.18
CD5+ CD4+	6.32	8.19	8.71	8.73	14.33	6.61

- %Live cells (CD5+ CD4+)
- %Live Cells (CD19+ CD5+)



**Emricasan & TNF** 

#### **CLL** cells are not sensitive to

killing by Emricasan

### **Drug Assay on CLL Cells**

%Live cells (CD5+ CD4+)

CD5+ CD4+


0.29

0.29

■ %Live Cells (CD19+ CD5+)

TNF (T): 10ng/mL
Biri (B): 0.5uM
Emrisacan (E): 25uM
Necrostatin (N): 50uM

0.66



0.52

0.46

0.47

0.26

100 m	1004 - 10	Single Calls 2 91.5 91.5	000 000 000 000 000 000 000 000 000 00
PSC	A	PSC-IV	SSC-A
Owny-V625_80.A::CD19 BV510	CD19+ CD5+ CLL Cells	250K - 150K - 15	CD15+ CD5+ CLL Live Cells 45.6 45.6 15 <sup>3</sup> 10 <sup>4</sup> 10 <sup>5</sup> 100p-8895_40-A : FI
Comp.ves0_50.A: CD4 69/421 20 0 20 20	CD5+ CD4+ CLL Cells  103 0 163 154 165  Comp-R6TD_3O-A :: CD5 APC	195K - 193 0	CD6+ CD4+ CLL Live Cells  10 <sup>3</sup> 10 <sup>4</sup> 10 <sup>5</sup> 10-8015_40-A : PI

#### **Summary**

- CLL cells are very sensitive to Venetoclax.
- CLL cells would show resistance to Venetoclax (20%).
- Emricasan is a potential way to solve the problem but it can not be used with TNF.

## Seminars and Workshops



#### eventbrite

Order no. 4016196119

#### Regulatory T cell Mini Symposium



#### In-person attendance ticket

G004 Auditorium, The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street, Melbourne, VIC 3000, Australia

Wednesday, 13 July 2022 from 1:00 pm to 5:30 pm (AEST)

Lauren Howson



#### Dr Christoph Grohman

Senior Research Officer - Lessene L

Target identification studies of a



Reconnect Symposium 2022, Tue

Registration Opens: 8.30 AM - 9:00 AM, WE

		IMMUNOLOGY SEMINAR SERIES 2022		
MONTH	DATE	SPEAKER(S)	CHAIR	VENUE
JULY	7	Lab Head Session: Charlotte Slade	Evan Thomas	DA/TEAMS
	14	Raymond Qin	Cindy Audiger	DA/TEAMS
	21	Sara Tomei (1hr)	Lucille Rankin	TEAMS ONLY
	28	Charis Teh Matthias Mulazzani	Esther Bandala Sanchez	DA/TEAMS
AUGUST	4	Lab Head Session: Misty Jenkins	Caleb Dawson	DA/TEAMS
	11	Lauren Howson Melinda Hardy	Charis Teh	DA/TEAMS
	18	Esmaeel Azadian Leesa Lertsumitkul	Julie Tellier	DA/TEAMS
	25	No Seminar: Andrew Lew Symposium		
SEPTEMBER	1	Lab Head Session: Vanessa Bryant	Matthias Mulazzani	DA/TEAMS

Invited Speaker: Pirooz Zareie (Monash)

ory Symposium

Order #4064904619

wearch, 1G Royal Parade, Level 7, Parkville, VIC

o 5:45 pm (AEST)

n 12 July 2022 4:49 pm

9:00AM - 9:10AM Davis auditorium Welcome to country


Introduction to MIN and the new MIN committee: Prof. Nick Huntington (MONASH)


Welcome to MIN Reconnect 2022: Dr Lorraine O'Reilly/Dr Cynthia Louis (WEHI)



40649046196526623709001

## **Experiments: Genotyping**







- **BAFF**


- Digesting the samples
- PCR
  - Preparing a PCR mix vial
  - Preparing a PCR test
  - Running a PCR program
- Running a Gel







# Experiments: Mice Bleed (Cells sorting)



Cre(+/+)


Cre(T/+)


BAFF-R(+/+) BAFF-R(+/+) BAFF-R(+/-) BAFF-R(-/-) BAFF-R(-/-)


Cre(+/+)

A dose effect exists.

# **Experiments: Antibody Titration**







## Acknowledgement

**Gray Lab** 

**Daniel Gray** 

**Charis Teh** 

**Tania Tan** 

Mengxiao Luo

**Lucille Rankin** 

**Kelin Zhao** 

**Alissa Robbins** 

**InSPIRE Team** 

**Jian-Guo Zhang** 

**Grant Dewson** 

Flow Cytometry

**Facility Staff** 

**Simon Monard** 

**Athena Huei Chen** 

**HuyBenny Nguyen** 

**Casey Anttila** 

**Stacey Woodrow** 

**Dora Kaminaris** 

**Chayanica Nasa** 

Michelle Cunningham

**Fudan University** 

Lin Sun

**Liang Cai** 

Zhenyu Zhu

**Host Family** 

Family & Friends









### Thank you



